You are herePOINT Investigators

POINT Investigators


Please note: The NINDS has discontinued further randomization into the POINT Trial based on the recommendation of the Data and Safety Monitoring Board (DSMB). There were no administrative concerns and follow-up of patients already randomized in the trial should continue per the protocol.

Click here for POINT Training and Resources including FAQs, Protocol, and POINT Toolbox.
The POINT 24-Hour Hotline is 1-866-94-POINT (1-866-947-6468).